Dexmedetomidine

Dexmedetomidine is used across multiple products and settings for sedation and agitation control. Here is the full set of approved uses:

• Sedation of adults who are intubated and on a mechanical ventilator (breathing machine) in the intensive care unit (ICU) — given as a continuous IV infusion for up to 24 hours
• Sedation of non-intubated adults before or during surgery and other procedures — given as an IV infusion
• Select injectable formulations (including Precedex and several dexmedetomidine hydrochloride products): sedation of non-intubated children aged 1 month to under 18 years before and during non-invasive procedures such as MRI scans
• Igalmi (sublingual film only): acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults — the safety and effectiveness of Igalmi have not been established beyond 24 hours from the first dose

Dexmedetomidine activates alpha-2 adrenergic receptors — sensors found mainly in the brain and nervous system. Stimulating these receptors reduces the signals that keep you awake and alert, producing a calm, sleepy state. At recommended doses, it does this without significantly suppressing breathing — an advantage over many other sedatives. At very high doses or with rapid administration, it can also activate a related receptor type (alpha-1), which can cause a brief rise in blood pressure.

All forms of dexmedetomidine are given only in a hospital or supervised clinical setting — never self-administered at home. The injectable forms are delivered as a continuous drip into a vein (intravenous infusion) using a controlled pump, and use is generally limited to no more than 24 hours. Igalmi is a film placed under the tongue in a supervised setting. Dosing is individualized — your care team adjusts it based on your response and the level of sedation needed.

• Older adults (over 65) and those with liver disease may need a lower dose
• Continuous monitoring of heart rate, blood pressure, and oxygen levels is required throughout treatment

The most common side effects reported in adults include:

• Low blood pressure (hypotension)
• Slow heart rate (bradycardia)
• Dry mouth
• Brief high blood pressure at the start of an IV infusion
• Nausea, vomiting, and agitation after stopping the infusion
• In children aged 1 month to under 17 years: slow breathing (bradypnea), slow heart rate, high blood pressure, and low blood pressure occur more frequently

Serious reactions — including dangerously slow heart rate, cardiac arrest, and respiratory failure — have been reported and require immediate medical attention. With infusions lasting more than 24 hours, ARDS (a severe lung condition) and respiratory failure have also been reported.

• Low blood pressure and slow heart rate: These are the most significant risks. They can require intervention and have rarely been fatal. Risk is highest in elderly patients, those with low fluid levels, diabetes, chronic high blood pressure, or serious heart conditions.
• Sinus arrest (the heart briefly stopping its normal rhythm): Reported in young, healthy individuals — especially with rapid IV delivery. Your team is prepared to respond immediately.
• Temporary blood pressure spike: A brief rise in blood pressure can happen at the start of the infusion; this usually resolves without treatment.
• Withdrawal effects: Stopping after prolonged use can cause nausea, vomiting, agitation, rapid heart rate, and high blood pressure.
• Tolerance: Using dexmedetomidine beyond 24 hours may cause it to become less effective over time.
• Alertness during sedation: Some patients can be roused (woken briefly) with stimulation — this does not necessarily mean the medication isn't working.

Dexmedetomidine can interact with other medicines used in hospital settings, potentially making their effects stronger:

• Anesthetics (e.g., sevoflurane, isoflurane): Combined use deepens sedation; lower doses of one or both drugs may be needed
• Sedatives and sleep medicines (e.g., propofol, midazolam): Additive sedative effects — dose reductions may be required
• Opioid pain medicines (e.g., alfentanil): Can enhance sedation and other effects when used together
• Blood pressure-lowering or heart-rate-slowing drugs (vasodilators, negative chronotropic agents): Use with caution — additive effects on blood pressure and heart rate

This is not a complete list of interactions. Always talk with your doctor or pharmacist before starting, stopping, or changing any medication.

• Older adults (65+): Higher risk of low blood pressure and slow heart rate — a lower dose is often considered
• Liver disease: The body clears dexmedetomidine more slowly; dose reduction may be needed
• Heart problems: Use with extra caution if you have advanced heart block or severe heart dysfunction
• Low blood volume, diabetes, or chronic high blood pressure: These conditions make blood pressure drops more likely
• Pregnancy: Dexmedetomidine crosses the placenta. Available human data have not shown a clear risk of birth defects, but animal studies showed some fetal harm at higher doses. Discuss risks and benefits with your doctor.
• Breastfeeding: Dexmedetomidine has been detected in breast milk. Monitor your baby for irritability if you breastfeed after receiving this medication.
• Children: The injectable form is approved for non-invasive procedural sedation in children aged 1 month to under 18 years — but has NOT been established for ICU sedation in children. Not approved in infants under 1 month old.
• Igalmi (sublingual film): Approved for adults only; safety beyond 24 hours from the first dose has not been established
• Kidney disease: Dexmedetomidine's processing in the body is not significantly affected by severe kidney disease, but your care team should be aware of all your medical conditions

Taking too much dexmedetomidine can cause an abnormally slow heart rate, dangerously low blood pressure, and serious heart rhythm problems including heart block. In extreme cases, cardiac arrest has occurred, though patients have been successfully resuscitated with prompt treatment. Overdose situations are managed entirely by the medical team in the hospital setting.

At doses within the recommended range, dexmedetomidine produces sedation while allowing breathing rate and blood oxygen levels to remain within normal limits — meaning it is much less likely to suppress breathing than many other sedatives. It works by reducing activity in the part of the nervous system that drives alertness, but patients can often still be briefly awakened with stimulation, then return to a calm state. This quality is considered a feature, not a sign that the drug isn't working.

After an IV dose, dexmedetomidine spreads rapidly through the body in about 6 minutes and is then cleared with a half-life (the time it takes blood levels to drop by half) of roughly 2 hours. It is almost completely broken down by the liver — very little leaves the body unchanged — with about 95% of the drug eventually excreted in the urine. About 94% of the drug binds to proteins in the blood while it circulates. People with significant liver disease clear it more slowly and may need lower doses; kidney disease does not significantly change how the drug is processed.

Store at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C to 30°C (59°F to 86°F).